Viromed Medical AG's Cold Plasma Technology Shows Promise in Reducing Deaths in Ventilated Patients

Viromed Medical AG, a leader in cold plasma technology, has announced promising preclinical study results regarding its potential to reduce mortality in ventilated patients. Conducted by the Hannover Medical School, the study highlights the use of cold plasma in tackling ventilator-associated pneumonia (VAP), a condition affecting up to 40% of mechanically ventilated patients in Germany annually.

CEO Uwe Perbandt states that early cold plasma treatment could prevent up to 6,000 deaths per year in Germany. The technology, showcased by the PulmoPlas® device, demonstrates significant antimicrobial efficacy without harming lung tissue. For every 100 VAP patients, early intervention might save two to three lives, marking a significant medical milestone.

Plans for special 'fast-track' approval are underway, with expectations set for late summer 2025. This approval will focus solely on Viromed's patented PulmoPlas® system.